We showed that cobimetinib, like the previously tested MEK inhibitors PD0325901 (Jessen et al, 2013) and selumetinib (Dombi et al, 2016), shrinks murine neurofibromas. This evidence concerns the gene MAP2K7 and neurofibroma.